HTBX - Heat Biologics: Investors Would Be Wise To Hold Off Until 2H 2021 Clinical Trial Interim Results
- Heat Biologics, Inc. is a clinical-stage biopharmaceutical stage company focused on developing immune therapies and vaccines.
- Heat Biologics' pipeline consists of three clinical-stage therapeutics and 1 pre-clinical (COVID-19 vaccine). Heat Biologics' lead therapeutic is HS-110 (viagenpumatucel-L), an off-the-shelf allogeneic cell-therapy aiming to treat non-small cell lung cancer.
- Heat Biologics, funded primarily from common-stock issuances (9m 2020: +$119M) and revenue ($2.3M) from NIH and CPRIT grants, is expected to commercialize by FYE 2025.
- In summary, the author projects Heat Biologics as a "hold" until 2H 2021's clinical results which if successful thereafter present a 4-5 year price target of $56 (+713% upside).
For further details see:
Heat Biologics: Investors Would Be Wise To Hold Off Until 2H 2021 Clinical Trial Interim Results